Ann: Positive DEP irinotecan clinical results presentation, page-56

@Geeenius
just my abreviation from way back then - the DEP irinotecan SN38-SPL9111 study protocol Phase 1/2 back in 2019
now looking at poster and mouse study to be presented 4 years later on oher indications

A.1	Member State Concerned	UK - MHRA
A.2	EudraCT number	2019-001318-40
A.3	Full title of the trial	A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SN38-SPL9111 (DEP®-SN38), a SN38 dendrimer conjugate, in patients with advanced solid tumours.
A.3.1	Title of the trial for lay people, in easily understood, i.e. non-technical, language	A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SN38-SPL9111 (DEP®-SN38), a SN38 dendrimer conjugate, in patients with advanced solid tumours.
A.3.2	Name or abbreviated title of the trial where available	SN38-SPL9111 in advanced solid tumours
A.4.1	Sponsor's protocol code number	SN38-SPL9111-001